CEO Michael Balkin buys 100,000 shares of HRZN at $4.34, +81.0% increase in holdings, stock -48.7% from 52-week high
Michael Balkin, Chief Executive Officer, purchased 100,000 shares at $4.34 on 2026-06-09, expanding his holdings from 123.5K to 223.5K shares. The stock trades 48.7% below its 52-week high of $8.46, and his prior buy at this ticker on 2024-12-16 delivered a 90d return of +7.8%, while a 2024-08-05 purchase yielded -10.8% over 90 days—a 50% hit rate on same-ticker buys. The company reported net income of $2.8M but was unprofitable over its most recent full fiscal year, creating a disconnect between recent profitability and underlying fundamentals that warrants scrutiny of the investment thesis.
Director Balkin Michael buys 20,000 shares of HRZN at $8.53; stock down -35.5% from 52-week high, unprofitable year.
Balkin Michael, a director, purchased 20,000 shares at $8.53 on 2024-12-16, establishing an initial position in HRZN. The stock has declined sharply from its 52-week high of $13.63 and is currently trading at $8.79, down -19.4% over 90 days. Notably, his prior buy at this ticker on 2024-08-05 returned -10.8% over 90 days, and his cross-ticker track record shows a 0% 90-day win rate despite prior near-term gains. The company reported negative full-year net income despite current-period positive earnings of $7.3M, creating mixed financial signals. The purchase occurs at a depressed valuation but within a persistent downtrend, with no clear evidence that the timing will reverse the recent pattern observed in this insider's prior activity at this ticker.
Director Balkin Michael purchases 10,000 shares of HRZN at $10.58; stock down 20.3% from 52-week high amid -$9.1M net loss.
Director Michael Balkin purchased 10,000 shares of Horizon Technology Finance at $10.58 on 2024-08-05, establishing an initial position in the company. The purchase occurred as HRZN traded -20.3% from its 52-week high of $13.63 and the company reported a full-year net loss of -$9.1M, making this a buy by a board member into a fundamentally unprofitable company at a depressed price level. The stock has continued to decline 30 days and 90 days post-purchase (-10.0% and -7.8% respectively), and current price of $10.86 sits only $0.28 above the transaction price. The transaction represents an initial stake rather than portfolio accumulation, but without visibility into broader board or management activity, the trade alone provides limited signal regarding company or director conviction at current valuations.
